Outlook Completes FDR Meeting With FDA For LYTENAVA In Treating Macular Degeneration

Outlook Therapeutics completed a federal dispute resolution meeting with the FDA over the regulatory pathway for ONS-5010/LYTENAVA. The update is procedural and provides no new approval decision or clinical data. The news is likely incremental for the stock rather than a major market mover.

Analysis

Outlook Therapeutics completed a federal dispute resolution meeting with the FDA over the regulatory pathway for ONS-5010/LYTENAVA. The update is procedural and provides no new approval decision or clinical data. The news is likely incremental for the stock rather than a major market mover.